Related Experiment Videos
Pneumococcal immunization in older adults: implications for the long-term-care setting
1Department of Clinical Epidemiology and Biostatistics, McMaster University and Hamilton Regional Laboratory Program, Hamilton, Ontario, Canada.
Infection Control and Hospital Epidemiology
|November 30, 2004
Summary
Pneumococcal polysaccharide vaccine shows efficacy in older adults, particularly in long-term-care facilities, despite limited clinical trial data. Observational studies consistently demonstrate its benefits, supporting its recommendation for this population.
Area of Science:
- Gerontology
- Immunology
- Public Health
Background:
- Pneumococcal polysaccharide vaccine (PPSV) is recommended for older adults.
- Efficacy data in elderly subpopulations and long-term-care facility (LTCF) residents require synthesis.
Purpose of the Study:
- Compare PPSV efficacy in older adults from clinical trials versus observational studies.
- Discuss implications for PPSV use in LTCFs.
Main Methods:
- Medline search to April 2003.
- Inclusion of meta-analyses of randomized/quasi-randomized trials and observational studies (cohort, case-control).
Main Results:
- Clinical trials (8 studies in adults ≥55 years) showed no significant protective effect, but lacked power.
- Observational studies (11 studies) demonstrated efficacy in 9/11 cases.
- Only one study specifically addressed LTCF residents.
Conclusions:
- Clinical trial subgroup analyses lacked statistical power.
- Observational studies consistently show PPSV efficacy in older adults.
- PPSV is cost-effective, safe, and recommended for older adults, especially LTCF residents.